Novo Nordisk’s decision will force people in developing countries to use outdated glass vials and syringes, warn campaigners
The pharmaceutical company behind injectable weight-loss drugs has been accused of prioritising profits over the health of people in developing countries by halting production of its insulin pens.
People living with type 1 diabetes who are reliant on the human insulin produced by Novo Nordisk, will instead be given glass vials and syringes – which they say are inconvenient and harder to use with the same accuracy.
About Author
More Stories
EU should spare carmakers from ‘punitive’ emissions fines, says Scholz
Record number of Chinese tourists expected to visit Australia this summer as market passes pre-pandemic peak
Musk’s conflicts of interest as Trump adviser could benefit him, experts warn